Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

NCT02305316 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: BIA 9-1067 non-micronized
DRUG: BIA 9-1067 micronized

Sponsor

Bial - Portela C S.A.